AEM ANR 18 Feb 22

AEM enters bear market despite analysts’ positive calls. What gives? (20 Feb 22)

Dear all AEM has fallen 21% from an intraday high of $5.37 on 14 Dec 2021 to close $4.25 on 18 Feb 2022. What has happened in the last two months to warrant such falls? Based on Bloomberg, average analyst target price is around $6.72, representing a potential capital upside of around 58%. Is this the bottom for AEM, or will it fall further? Personally, I think AEM is worth a closer look at $4.20 – 4.30 region. Let’s take a look at its investment merits and risks.   First things first, what does AEM do? According to its company […]

Table 1_Ave premium to VWAP

My thoughts on Sing Medical Group’s possible share transaction (29 Dec 20)

Dear all Sing Medical Group (“SMG”) announced on 18 Dec 20 that the Company is currently in discussions with a third party regarding a possible transaction involving the Company’s shares. The discussions are preliminary and there is no certainty or assurance that such discussions will progress beyond the current stage or that any transaction will materialise as a result of such discussions.   Why am I interested in SMG? My personal view is that at $0.315, given a potential share transaction scenario, the risk reward seems favourable. Please refer to my basis and the risks as highlighted below: 1) Past […]

Peer comparison 17 Sep 2019

Unusual – Challenging its key resistance $0.270 – 0.280 with volume expansion (4 Nov 2019)

Last Friday, Unusual Limited (“Unusual”) caught my attention. It is testing its key resistance $0.270 – 0.280, accompanied by an increase in volume for the past three days with above average volume in two out of the past three days. It closed at $0.275 on 4 Nov 2019. Day range 0.270 – 0.280. Furthermore, as its 2QFY20F results are just around the corner, it may be an opportune time to take a look at this stock.   Interesting points A) Chart looks positive with strengthening indicators and volume Based on Chart 1 below, Unusual has been challenging its key resistance […]